Charts

Over the last year, a good number of insiders have significantly increased their holdings in IGM Biosciences, Inc...

In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range of perspectives ...

Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseasesMOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus ex

MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of t

Investors considering a purchase of IGM Biosciences Inc (IGMS) stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $5 strike, which has a bid at the time of this writing of 40 cents..

Investors considering a purchase of IGM Biosciences Inc (IGMS) stock, but tentative about paying the going market price of $9.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $5 strike, which has a bid at the time of this writing of 50 cents..

IGM Biosciences ( NASDAQ:IGMS ) Full Year 2023 Results Key Financial Results Net loss: US$246.4m (loss widened by 11...

Across the recent three months, 4 analysts have shared their insights on IGM Biosciences (NASDAQ:IGMS), expressing a variety of opinions ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IGMS stock results show that IGM Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. The post IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. “We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potentia

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco NASDAQ Future Gen 200 ETF (QQQS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $39.79 per unit.

The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter ...

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) ...

RBC Capital upgraded IGM Biosciences Inc (NASDAQ:IGMS), a biotechnology focused on antibody medicines for cancer. RBC analysts ...

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter ...

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) ...

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco NASDAQ Future Gen 200 ETF (QQQS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $38.16 per unit.

U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday. Shares of Morgan Stanley (NYSE: MS) fell ...

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Acuity Brands, Inc. (NYSE: AYI) rose ...

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the

Investors eyeing a purchase of IGM Biosciences Inc (IGMS) stock, but tentative about paying the going market price of $8.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2024 put at the $7.50 strike, which has a bid at the time of this writing of $1.45..

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday. Shares of ZimVie Inc. (NASDAQ: ZIMV) ...

Gainers Onconova Therapeutics (NASDAQ:ONTX) shares moved upwards by 42.5% to $0.9 during Friday's after-market session. The company's ...

In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]

HC Wainwright & Co. downgraded its rating of IGM Biosciences (NASDAQ:IGMS) to Neutral with a price target of $7.00, changing its ...

Over the past 3 months, 5 analysts have published their opinion on IGM Biosciences (NASDAQ:IGMS) stock. These analysts are typically ...

IGM Biosciences Inc(NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 ...

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indications halted – – Cash runway expected to extend into second quarter 2026 – – Reduction in workforce of approximately 22 percent – MOUNTAIN VIEW, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnol

Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm. For more detailed information on the content of the resolution, please see the complete notice of the extraordinary general meeting that is available on the Company's website, www.medivir.com. Minutes from the extraordinary general meeting will be provided on the said

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Continued Clinical Development and Financial Guidance for 2023

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. “During the third quarter, we continued to execute across our clinical development pipeline,”

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $98.24 per unit.

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $290.92 per unit.

Investors eyeing a purchase of IGM Biosciences Inc (IGMS) stock, but tentative about paying the going market price of $7.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2024 put at the $5 strike, which has a bid at the time of this writing of 55 cents..

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $27.70 per unit.

IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Looking back to 47 days ago, IGM Biosciences Inc (IGMS) priced a 10,597,827 share secondary stock offering at $8.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

In trading on Monday, shares of IGM Biosciences Inc (IGMS) touched a new 52-week low of $8.04/share. That's a $20.16 share price drop, or -71.49% decline from the 52-week high of $28.20 set back on 11/15/2022..

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $213.17 per unit.

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

Investors eyeing a purchase of IGM Biosciences Inc (IGMS) stock, but tentative about paying the going market price of $9.59/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7.50 strike, which has a bid at the time of this writing of 95 cents..

Stocks are attempting a rebound this afternoon, following their third-straight day of losses.

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of ...

U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in ...

IGM Biosciences Inc (NASDAQ: IGMS) shares are trading higher by 11.69% to $9.89 Thursday morning after the company priced upsized public ...

U.S. stocks traded lower this morning, with Nasdaq Composite dropping over 150 points on Thursday. Following the market opening ...

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to ...

U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Dick's Sporting Goods, Inc (DKS), where a total of 12,382 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 70.3% of DKS's average daily trading volume over the past month of 1.8 million shares..

IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

IGM Biosciences (NASDAQ:IGMS) reported its Q1 earnings results on Friday, May 12, 2023 at 09:05 AM. Here's what investors need to know ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco NASDAQ Future Gen 200 ETF (QQQS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.34 per unit.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 8, IGM Biosciences Inc's Director, M..